ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or

Evaluation of the Efficacy and Tolerance of the Association ATEZOLIZUMAB - BEVACIZUMAB in the Treatment of a Locally Advanced Hepatocellular Carcinoma Inoperable or Metastatic in Finistère

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04730388

Acronym

HEPATOFIT

Enrollment

100

Registered

2021-01-29

Start date

2021-01-18

Completion date

2022-01-18

Last updated

2021-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Hepatocellular Carcinoma

Keywords

ATEZOLIZUMAB, BEVACIZUMAB , Advanced hepatocellular carcinoma

Brief summary

Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère

Detailed description

Patients treated by ATEZOLIZUMAB and BEVACIZUMAB for an Advanced hepatocellular carcinoma will be followed to observed their safety and the efficacy of this treatment, and to identify prongnosis factors

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment * Child Pugh A and ECOG 0 or 1 * upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated * non eligible to receive a locoregional therpay or progressive after this kinf of treatment * with informed consent

Exclusion criteria

* refuse to participate * under legal protection *

Design outcomes

Primary

Measure	Time frame	Description
predictive factor for progression-free survival	12 months	progression-free survival = time between treatment initiation and rediologic or clinical progression

Contacts

Primary ContactPierre-Guillaume Poureau, MD

pierre-guillaume.poureau@chu-brest.fr0298223740

Outcome results